BART service between Berkeley, Richmond halted due to medical emergency
BART service between the Berkeley and Richmond stations Friday morning has been halted due to a medical emergency, officials said.
Around 6:50 a.m., the agency announced on social media that service was stopped following reports of a "major medical emergency" outside of the North Berkeley station. Additional details about the emergency were not immediately available.
BART service has stopped between Downtown Berkeley and Richmond stations due to a major medical emergency outside of North Berkeley station. AC Transit is providing bus service between Richmond and Berkeley stations. — BART Alert (@SFBARTalert) June 13, 2025
BART said AC Transit is providing bus service between Richmond and Berkeley stations.
Friday's incident is the second service disruption due to a medical emergency in as many days. On Thursday morning, an emergency at the Hayward station halted service for two hours between Bayfair and the South Hayward stations.
This is a breaking news update. More details to come.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Edinburgh dad's heartbreak as baby's everyday symptom leads to devastating diagnosis
An Edinburgh dad has opened up on his family's devastation after their son's first birthday party led to a rare diagnosis. Marc Robson and his partner Melinda Garratt noticed their little boy Finley wasn't his usual self on the day of his party, and he started throwing up. Finley still wasn't feeling right the day after, so the family decided to call 111. Melinda, 31, and Marc, 32, said they were advised to visit a pharmacist. They were told it may be due to Finley transitioning from formula to cow's milk, though this didn't help his condition. READ MORE: Edinburgh police swoop on residential street as 'emergency incident' unfolds READ MORE: Edinburgh dad's new career after going viral on Facebook 'by chance' After several trips to A&E, Finley began vomiting blood. Finley was eventually rushed to Newcastle's Royal Victoria Infirmary, where doctors found a tumour on his brain. Marc, who grew up in Edinburgh before starting a family in Newcastle, told Chronicle Live: "When we initially went to the RVI we thought it was going to be stomach issues, so hearing it was a tumour was very tough. "The only way I can describe it is it was almost like I wasn't in my own body when I was hearing it. It was a strange feeling. Melinda was in tears." Finley underwent an operation the following day which removed the majority of the tumour from his brain. Marc said: "They took him away from us at about 9.30am and we didn't see him again until 6.30pm. It was a very, very long day." Sign up for Edinburgh Live newsletters for more headlines straight to your inbox Approximately one week later the family received preliminary results which revealed the tumour could be one of four aggressive forms. And on Monday (June 23) the family received the heartbreaking news that Finley's tumour was the most aggressive of the four - an Atypical Teratoid Rhabdoid Tumor (ATRT) - an extremely rare form of brain cancer. Finley will now begin chemotherapy on Monday (June 30). Marc said: "I'm not sure if it has even sunk in fully for us yet. We've had quite a few sleepless nights. It's so hard to explain what it's like hearing the news. It's almost as if you're watching someone else get that news. "I think the next stage when he has the chemo is when it's going to hit the most. When we need to manage the treatment and his wellbeing even more than we already do. "Contact with family and friends is going to be non-existent because of the side effects and his immune system going down. And when he loses his hair we've decided that we're going to shave it off to get it over and done with. "The doctor recommended we do that too because we didn't realise but when babies go through this they can easily choke on their hair when they're sleeping. We'll shave it off when we feel that his scars have healed from his operation." Finley will receive chemotherapy for the next five months before undergoing tests to see if it has been successful. Reflecting on how Finley has been coping with treatment, Marc said: "He doesn't talk other than he's recently started saying 'dada' so he can't really tell you what's wrong. "But you can tell he's been in a lot of pain since the operation, which is normal. After his first operation he didn't really move much, he was sleeping a lot and couldn't lift his head up so we had to hold him. Join Edinburgh Live's Whatsapp Community here and get the latest news sent straight to your messages. "He used to love rolling around but you could see that it was frustrating him when he was trying to move but he couldn't because he was in pain and he didn't quite understand why he was in pain." The couple have set up a GoFundMe page to help ease the financial burden they have already encountered since Finley became unwell. Marc, who works as a business development manager for a company which provides maintenance for care homes, is currently receiving full pay. However, he is unsure how much he will be able to work once Finley begins chemo. Melinda, who works for Lookers car sales company, is currently off work. As well as helping to manage bills and any unexpected costs that arise as the couple navigate treatments and time away from work, the money raised will also help the couple with hospital parking fees and travel expenses. For more information and how to donate visit the GoFundMe page here.
Yahoo
4 hours ago
- Yahoo
Cal Fire awards $5.9M in forest health research grants to tackle wildfires
(FOX 5/KUSI) — In a push to strengthen California's forest resilience and wildfire preparedness, the California Department of Forestry and Fire Protection (Cal Fire) has awarded $5.9 million in grants to support 15 cutting-edge scientific research projects aimed at improving forest practices, land management, and public education. Announced on Friday, the funding comes from the Forest Health Research Program, a key component of the state's California Climate Investments initiative, supported by Greenhouse Gas Reduction Funds and the Wildfire and Forest Resilience budget package. 'These grant awards from the Forest Health Research Program are filling critical gaps in our knowledge of fire, forest, and other vegetation management,' said Chris Keithley, Cal Fire's assistant deputy director of Fire and Resource Assessment. 'The researchers we support fill knowledge gaps, evaluate effectiveness of management practices, develop new tools, and create vital information as we continue to work towards a more resilient California.' NASA research planes to conduct low-altitude flights over Southern California According to Cal Fire, the funded studies will explore understudied vegetation types such as chaparral, mountain meadows and oak woodlands, all of which play vital roles in California's ecological landscape. Other projects will advance tools for prescribed fire planning, forest monitoring and the cost-benefit evaluation of fuel treatment strategies, offering science-backed guidance to forest landowners, public agencies, fire response teams, and policymakers across the state. Among the recipients are academic and research institutions including the University of California, California State University, Colorado State University, Desert Research Institute, the USDA Forest Service, and Resources for the Future. Notably, six of the projects will be led by graduate students, fostering a new generation of experts in fire science and forest ecology. The grant-funded projects are expected to yield scientific publications, educational events, and decision-making tools that will support communities and agencies in mitigating wildfire risks and managing forest health more effectively, said Cal Fire officials. The Forest Health Research Program was created to address pressing questions related to climate change impacts, wildfire behavior, carbon storage, and land-use practices. Its goal, according to Cal Fire, is to provide the scientific foundation needed to develop long-term, sustainable forest management strategies across California. A full list of awarded projects and an interactive map of past and current research is available on the Forest Health Research website at: Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
5 hours ago
- Yahoo
Goldman Sachs Reaffirms 'Buy' Rating on Iovance (IOVA) for Positive Amtagvi Data
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 10 best healthcare penny stocks to buy according to analysts. Goldman Sachs reiterated its 'Buy' rating on Iovance's stock on June 3. The firm also maintained its $34.00 price target for Iovance shares. A close up of a lab technician in a protective suit, working with cells in a petri dish to develop innovative therapeutics for immune-related diseases. Goldman Sachs based its reaffirmation on new data that Iovance presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO data focused on Amtagvi, a tumor-infiltrating lymphocyte (TIL) therapy. The FDA approved the treatment in February 2024 for adult patients with unresectable or metastatic melanoma. The data supported the therapy's safety profile, which, according to Goldman Sachs, reinforces Amtagvi's potential as a significant treatment option. Goldman Sachs's analysts noted that the five-year follow-up data are unprecedented for any therapy in this heavily pretreated advanced melanoma population. To them, the data highlights the durability of Amtagvi's responses. The firm emphasized Amtagvi's successful US launch, with consistent patient demand, enhanced operations at Authorized Treatment Centers (ATCs), and improved out-of-spec rates (manufacturing quality metrics). It also highlighted the drug's first full calendar year of sales in 2025 as a key driver. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a commercial-stage biopharmaceutical company. It develops and markets cell therapies that harness a patient's own immune cells to treat solid tumors. Its lead product is Amtagvi, approved for advanced melanoma, and it also markets Proleukin. Iovance's pipeline includes candidates for cervical cancer, non-small cell lung cancer, and hematologic malignancies. While we acknowledge the potential of IOVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
